Abstract 710P
Background
Early-phase clinical trials are a unique opportunity for patients with cancer to benefit from innovative treatments. These trials usually demand newly-collected tumor tissue for research purpose, requiring patients to undergo new biopsies. Some trials require a prescreening by next-generation sequencing (NGS), but the analysis can be challenged by both the quality and the quantity of the samples. Biopsies may have procedural complications with negative impact on patients.
Methods
We retrospectively reviewed the records of patients referred to the Early Drug Development (EDD) Unit of European Institute of Oncology, who performed fresh biopsies for research purpose. We aimed at assessing safety of the biopsies and the adequacy of the tumor tissue for NGS testing.
Results
A total of 731 patients were referred to the EDD Unit from January 2014 to December 2022. Median age was 56 years (range 20 – 83) and 79% of patients were female. The most common tumor type was breast cancer (40%), followed by lung adenocarcinoma (6.2%), cholangiocarcinoma (5.8%), and carcinoma of unknown primary (5.8%). Three hundred fifty-five patients (48.6%) underwent a new biopsy at trial entry. Liver (148, 41.7%), lymph nodes (64, 18%), skin (47, 13.2%) and breast (7.3%) were the most frequent sites for biopsy. The median time from trial’s informed consent to biopsy was 3 days (range 0 – 83). The tumor tissue was commonly adequate for histological diagnosis (98%); NGS testing was successful in 122 (88.4%) of the 138 cases in which the trial required NGS testing. Nine out of the 16 unsuccessful NGS were performed on liver tissue. Eleven patients (3.1%) had procedural complications from the biopsy (5 pain, 3 minor bleeding, 2 pneumothoraxes, 1 bradycardia), but none required hospitalization nor led to sequelae. The only treatments administered were painkillers.
Conclusions
Approximately half of the patients referred to our EDD Unit performed a fresh biopsy. The procedure was generally safe, with only a minority of patients (3%) having non-serious complications. About 10% of NGS failed due to poor sample quality or quantity, highlighting the importance to implement specific information and Standard Operating Procedure for samples intended for NGS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Edoardo Crimini.
Funding
Has not received any funding.
Disclosure
D. Trapani: Other, EMA Healthcare Professional Working Party (HCPWP), member: European Medicines Agency (EMA); Other, EML Cancer Medicines Working Group (CMWG), member: World Health Organization (WHO); Other, Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), chair: World Health Organization (WHO). C. Criscitiello: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Eli-Lilly, Roche, Gilead; Financial Interests, Personal, Advisory Board: MSD, Seagen, AstraZeneca, Daiichi Sankyo. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Coordinating PI, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17